nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.04.2012

Autoimmunity and Environment: Am I at risk?

verfasst von: Daniel Smyk, Eirini I. Rigopoulou, Harold Baum, Andrew K. Burroughs, Diego Vergani, Dimitrios P. Bogdanos

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The complex interplay between environmental factors and genetic susceptibility plays an essential role in disease pathogenesis. This is especially true for autoimmunity, where clinical reports, genomic and epidemiological studies, as well as animal models have identified several environmental and genetic risk factors associated with autoimmune disease. The complexity of this relationship is demonstrated by the vast array of environmental factors that have now been implicated in the induction, and possibly the maintenance of autoimmune disease. The multitude of environmental factors implicated includes both infectious and non-infectious agents. Here, we review one specific autoimmune disease, primary biliary cirrhosis (PBC), as a model for environmental risk factors acting in concert with genetic susceptibility in the disease pathogenesis. PBC is an ideal model, as both infectious and non-infectious environmental agents have been identified as risk factors, and their study provides clues for unravelling the pathogenesis of the disease.

Mackay IR (2005) The etiopathogenesis of autoimmunity. Semin Liver Dis 25(3):239–250PubMedCrossRef

Hewagama A, Richardson B (2009) The genetics and epigenetics of autoimmune diseases. J Autoimmun 33(1):3–11PubMedCrossRef

Wandstrat A, Wakeland E (2001) The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2(9):802–809PubMedCrossRef

Ahmed SA, Hissong BD, Verthelyi D, Donner K, Becker K, Karpuzoglu-Sahin E (1999) Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect 107(Suppl 5):681–686PubMedCrossRef

Coppieters KT, von Herrath MG (2011) Viruses and Cytotoxic T Lymphocytes in Type 1 Diabetes. Clin Rev Allergy Immunol (in press)

Christen U, Hintermann E, Holdener M, von Herrath MG (2010) Viral triggers for autoimmunity: is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmun 34(1):38–44PubMedCrossRef

Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34(3):J247–257PubMedCrossRef

Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38(3):235–245PubMedCrossRef

Bach JF (2005) Infections and autoimmune diseases. J Autoimmun 25(Suppl):74–80PubMedCrossRef

10.

Leslie RD, Hawa M (1994) Twin studies in auto-immune disease. Acta Genet Med Gemellol Roma 43(1–2):71–81PubMed

11.

Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME (2004) Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 127(2):485–492PubMedCrossRef

12.

Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, Fortin PR (2010) Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 49(11):2172–2180CrossRef

13.

Jarvinen P, Aho K (1994) Twin studies in rheumatic diseases. Semin Arthritis Rheum 24(1):19–28PubMedCrossRef

14.

Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34(3):J163–J167PubMedCrossRef

15.

Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME (2008) The consequences of apoptosis in autoimmunity. J Autoimmun 31(3):257–262PubMedCrossRef

16.

Chang C, Gershwin ME (2010) Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 34(3):J266–275PubMedCrossRef

17.

Costenbader KH, Karlson EW (2006) Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15(11):737–745PubMedCrossRef

18.

Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM (2005) Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 42(5):1194–1202PubMedCrossRef

19.

Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34(3):J258–265PubMedCrossRef

20.

Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S (2010) Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 69(1):70–81PubMedCrossRef

21.

Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M (2008) Is autoimmunity a matter of sex? Autoimmun Rev 7(8):626–630PubMedCrossRef

22.

Levy Y, Rotman-Pikielny P, Ehrenfeld M, Shoenfeld Y (2009) Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. Lupus 18(13):1226–1232PubMedCrossRef

23.

Bogdanos DP, Rigopoulou EI (2006) Self-mimicking autoimmune domains of hepatitis C virus core antigen. Vaccine 24(37–39):6173–6174PubMedCrossRef

24.

Bogdanos DP, Rigopoulou EI (2007) Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. Diab Res Clin Pract 77(1):155–156CrossRef

25.

Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D (2005) A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 12(3):217–224PubMedCrossRef

26.

Nancy AL, Shoenfeld Y (2008) Chronic fatigue syndrome with autoantibodies—the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 8(1):52–55PubMedCrossRef

27.

Cooper GS, Parks CG (2004) Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep 6(5):367–374PubMedCrossRef

28.

Parks CG, Conrad K, Cooper GS (1999) Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(Suppl 5):793–802PubMedCrossRef

29.

Pfau JC, Brown JM, Holian A (2004) Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology 195(2–3):167–176PubMedCrossRef

30.

Brown JM, Archer AJ, Pfau JC, Holian A (2003) Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 131(3):415–421PubMedCrossRef

31.

Parks CG, Cooper GS (2006) Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 15(11):728–736PubMedCrossRef

32.

Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli-Vergani G, Bianchi FB, Vergani D (2004) Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 17(1):83–92PubMed

33.

Bogdanos DP, McFarlane IG (2003) Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity. J Hepatol 39(5):860–863PubMedCrossRef

34.

Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142PubMedCrossRef

35.

Kriegel MA, Manson JE, Costenbader KH (2011) Does Vitamin D Affect Risk of Developing Autoimmune Disease?: A Systematic Review. Semin Arthritis Rheum (in press)

36.

Lerner A, Shapira Y, Agmon-Levin N, Pacht A, Ben-Ami Shor D, Lopez HM, Sanchez-Castanon M, Shoenfeld Y (2011) The Clinical Significance of 25OH-Vitamin D Status in Celiac Disease. Clin Rev Allergy Immunol (in press)

37.

Pelajo CF, Lopez-Benitez JM, Miller LC (2010) Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 9(7):507–510PubMedCrossRef

38.

Broder AR, Tobin JN, Putterman C (2010) Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther 12(5):R191PubMedCrossRef

39.

van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1alpha, 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23(3):233–239PubMedCrossRef

40.

Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, Daniel KC, Maghazachi AA, Belardelli F, Adorini L, Gessani S (2005) Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 174(1):270–276PubMed

41.

Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353(12):1261–1273PubMedCrossRef

42.

Hohenester S, Oude-Elferink RP, Beuers U (2009) Primary biliary cirrhosis. Semin Immunopathol 31(3):283–307PubMedCrossRef

43.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50(1):291–308PubMedCrossRef

44.

Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986) Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6(6):1279–1284PubMedCrossRef

45.

Neuberger J (1997) Primary biliary cirrhosis. Lancet 350(9081):875–879PubMedCrossRef

46.

Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF (2004) Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53(6):865–870PubMedCrossRef

47.

Bogdanos DP, Komorowski L (2011) Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 412(7–8):502–512PubMedCrossRef

48.

Bogdanos DP, Invernizzi P, Mackay IR, Vergani D (2008) Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 14(21):3374–3387PubMedCrossRef

49.

Bogdanos DP, Baum H, Vergani D (2003) Antimitochondrial and other autoantibodies. Clin Liver Dis 7(4):759–777PubMedCrossRef

50.

Kumagi T, Heathcote EJ (2008) Primary biliary cirrhosis. Orphanet J Rare Dis 3:1PubMedCrossRef

51.

James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (1999) Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 30(2):390–394PubMedCrossRef

52.

Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ 3rd, Dickson ER (2000) Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119(6):1631–1636PubMedCrossRef

53.

Dahnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stocker W, Komorowski L (2009) New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 55(5):978–985PubMedCrossRef

54.

Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P, Czaja AJ, Heathcote EJ, Hirschfield GM, Tan EM, Miyachi K, Bignotto M, Battezzati PM, Lleo A, Leung PS, Podda M, Gershwin ME (2010) Invernizzi P PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 35(4):436–442PubMedCrossRef

55.

Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D (2007) Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 27(9):1226–1231PubMedCrossRef

56.

Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, Dalekos GN (2007) Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 380(1–2):118–121PubMedCrossRef

57.

Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN (2007) Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 27(4):378–387PubMedCrossRef

58.

Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, Dickson ER, Homburger HA (1997) Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 25(1):6–11PubMedCrossRef

59.

Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P (2006) Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43(5):1135–1144PubMedCrossRef

60.

Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L, Dalekos GN, Rodes J, Vergani D (2007) Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 45(6):1583–1584PubMedCrossRef

61.

Bogdanos DP, Liaskos C, Rigopoulou EI, Dalekos GN (2006) Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. Clin Chim Acta 373(1–2):183–185PubMedCrossRef

62.

Bogdanos DP, Pares A, Rodes J, Vergani D (2004) Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol 99(4):763–765PubMedCrossRef

63.

Bogdanos DP, Vergani D, Muratori P, Muratori L, Bianchi FB (2004) Specificity of anti-sp100 antibody for primary biliary cirrhosis. Scand J Gastroenterol 39(4):405–407PubMedCrossRef

64.

Courvalin JC, Worman HJ (1997) Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 17(1):79–90PubMedCrossRef

65.

Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M (1997) Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25(5):1090–1095PubMedCrossRef

66.

Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34(3):366–372PubMedCrossRef

67.

Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, Shibata M, Onozuka Y, Ueno Y, Hashimoto E, Hayashi N, Shibuya A, Amaki S, Miyakawa H (2003) Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 20(3):247–254PubMedCrossRef

68.

Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98(2):431–437PubMedCrossRef

69.

Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, Rodes J, Dalekos GN, Vergani D (2005) Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54(4):528–532PubMedCrossRef

70.

Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, Gershwin ME, Rowley MJ (2000) The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 174:226–237PubMedCrossRef

71.

Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 47(2):737–745PubMedCrossRef

72.

Vergani D, Bogdanos DP, Baum H (2004) Unusual suspects in primary biliary cirrhosis. Hepatology 39(1):38–41PubMedCrossRef

73.

Hirschfield GM, Heathcote EJ, Gershwin ME (2010) Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 139(5):1481–1496PubMedCrossRef

74.

Jones DE (2007) Pathogenesis of primary biliary cirrhosis. Gut 56(11):1615–1624PubMed

75.

Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100(3):822–833PubMed

76.

Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, Jones DE, James OF, Bassendine MF (2006) HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44(3):667–674PubMedCrossRef

77.

Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, Mason AL, Myers RP, Peltekian KM, Ghent CN, Coltescu C, Atkinson EJ, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360(24):2544–2555PubMedCrossRef

78.

Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F, Selmi C, Lupoli S, Shigeta R, Ransom M, Lleo A, Lee AT, Mason AL, Myers RP, Peltekian KM, Ghent CN, Bernuzzi F, Zuin M, Rosina F, Borghesio E, Floreani A, Lazzari R, Niro G, Andriulli A, Muratori L, Muratori P, Almasio PL, Andreone P, Margotti M, Brunetto M, Coco B, Alvaro D, Bragazzi MC, Marra F, Pisano A, Rigamonti C, Colombo M, Marzioni M, Benedetti A, Fabris L, Strazzabosco M, Portincasa P, Palmieri VO, Tiribelli C, Croce L, Bruno S, Rossi S, Vinci M, Prisco C, Mattalia A, Toniutto P, Picciotto A, Galli A, Ferrari C, Colombo S, Casella G, Morini L, Caporaso N, Colli A, Spinzi G, Montanari R, Gregersen PK, Heathcote EJ, Hirschfield GM, Siminovitch KA, Amos CI, Gershwin ME, Seldin MF (2010) Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42(8):658–660PubMedCrossRef

79.

Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA (2010) Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 42(8):655–657PubMedCrossRef

80.

Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, Hirschfield GM, Siminovitch KA, Lazaridis KN (2010) Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 52(1):223–229PubMedCrossRef

81.

Selmi C, Mackay IR, Gershwin ME (2007) The immunological milieu of the liver. Semin Liver Dis 27(2):129–139PubMedCrossRef

82.

Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME (2001) Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 33(1):16–21PubMedCrossRef

83.

Prince MI, Ducker SJ, James OF (2010) Case–control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59(4):508–512PubMedCrossRef

84.

Corpechot C, Chretien Y, Chazouilleres O, Poupon R (2010) Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 53(1):162–169PubMedCrossRef

85.

Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S (1984) Bacteriuria and primary biliary cirrhosis. Gut 25(2):133–137PubMedCrossRef

86.

Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK (1993) M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 17(3):408–414PubMedCrossRef

87.

Butler P, Hamilton-Miller JM, McIntyre N, Burroughs AK (1995) Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 36(6):931–934PubMedCrossRef

88.

Morreale M, Tsirigotis M, Hughes MD, Brumfitt W, McIntyre N, Burroughs AK (1989) Significant bacteriuria has prognostic significance in primary biliary cirrhosis. J Hepatol 9(2):149–158PubMedCrossRef

89.

Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y (1995) HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181(5):1835–1845PubMedCrossRef

90.

Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, Ishibashi H (2000) Mimicry peptides of human PDC-E2 163–176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 31(6):1212–1216PubMedCrossRef

91.

Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, Lake J, Keeffe EB, Roche TE, Gershwin ME (1998) Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 102(10):1831–1840PubMedCrossRef

92.

Tanimoto H, Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Matsushita S, Gershwin ME, Harada M (2003) Promiscuous T cells selected by Escherichia coli: OGDC-E2 in primary biliary cirrhosis. J Autoimmun 20(3):255–263PubMedCrossRef

93.

Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D (2004) Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 40(1):31–39PubMedCrossRef

94.

Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, Vergani D (2002) Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 36(1):14–21PubMedCrossRef

95.

Bogdanos DP, Vergani D (2009) Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 36(1):30–39PubMedCrossRef

96.

Baum H, Bogdanos DP, Vergani D (2001) Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol 34(5):785–787PubMedCrossRef

97.

Van de Water J, Ishibashi H, Coppel RL, Gershwin ME (2001) Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology 33(4):771–775PubMedCrossRef

98.

Palermo JJ (2008) Recurrent urinary tract infection in mice results in immune-mediated cholangiopathy similar to human primary biliary cirrhosis. Gastroenterology 134(4, suppl 1):A837

99.

Burroughs AK, Butler P, Sternberg MJ, Baum H (1992) Molecular mimicry in liver disease. Nature 358(6385):377–378PubMedCrossRef

100.

Bogdanos DP, Baum H, Vergani D, Burroughs AK (2011) The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Disease Markers (in press)

101.

Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D (2003) Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 35(11):801–805PubMedCrossRef

102.

Bogdanos DP, Baum H, Gunsar F, Arioli D, Polymeros D, Ma Y, Burroughs AK, Vergani D (2004) Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterol 39(10):981–987PubMedCrossRef

103.

Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D (2005) Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 42(2):458–465PubMedCrossRef

104.

Bogdanos DP, Choudhuri K, Vergani D (2001) Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21(4):225–232PubMedCrossRef

105.

Selmi C, Meda F, Kasangian A, Invernizzi P, Tian Z, Lian Z, Podda M, Gershwin ME (2010) Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 7(1):1–10PubMedCrossRef

106.

Selmi C, Gershwin ME (2009) The role of environmental factors in primary biliary cirrhosis. Trends Immunol 30(8):415–420PubMedCrossRef

107.

Koutsoumpas A, Mytilinaiou M, Polymeros D, Dalekos GN, Bogdanos DP (2009) Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastroenterol Hepatol 21(10):1220PubMedCrossRef

108.

Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G (2009) Autoimmune hepatitis. Semin Immunopathol 31(3):421–435PubMedCrossRef

109.

Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, Vergani D (2001) Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 1(3):379–389PubMedCrossRef

110.

Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38(5):1250–1257PubMedCrossRef

111.

Polymeros D, Bogdanos DP, Day R, Arioli D, Vergani D, Forbes A (2006) Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn’s disease? Gastroenterology 131(1):85–96PubMedCrossRef

112.

Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell 50(6):819–820PubMedCrossRef

113.

Muratori L, Bogdanos DP, Muratori P, Lenzi M, Granito A, Ma Y, Mieli-Vergani G, Bianchi FB, Vergani D (2005) Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 3(6):595–603PubMedCrossRef

114.

Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D (2006) Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130(3):868–882PubMedCrossRef

115.

Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D (2003) Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170(3):1481–1489PubMed

116.

Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, Garson J, Bogdanos DP, Vegnente A, Mieli-Vergani G, Vergani D (2003) Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 133(3):404–413PubMedCrossRef

117.

Bogdanos DP, Mieli-Vergani G, Vergani D (2000) Virus, liver and autoimmunity. Dig Liver Dis 32(5):440–446PubMedCrossRef

118.

Bogdanos DP, Muratori L, Bianchi FB, Vergani D (2000) Hepatitis C virus and autoimmunity. Hepatology 31(6):1380PubMedCrossRef

119.

Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, Burroughs AK, Rodes J, Vergani D (2004) Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun 22(4):353–362PubMedCrossRef

120.

Bogdanos DP, Koutsoumpas A, Baum H, Vergani D (2006) Borrelia Burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis 38(10):781–783PubMedCrossRef

121.

Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U (2008) Primary biliary cirrhosis following lactobacillus vaccination for recurrent vaginitis. J Hepatol 49(3):466–473PubMedCrossRef

122.

Baum H (1995) Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim Biophys Acta 1271(1):111–121PubMed

123.

Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M, Attili AF, Podda M, Gaudio E (2004) Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 41(6):905–912PubMedCrossRef

124.

Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J, Suen YF, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Matsuura E, Coppel RL, Gershwin ME (2005) Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174(9):5874–5883PubMed

125.

Amano K, Leung PS, Xu Q, Marik J, Quan C, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Coppel RL, Gershwin ME (2004) Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 172(10):6444–6452PubMed

126.

Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, Colvin ME, Lam KS, Coppel RL, Ansari A, Gershwin ME (2001) Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 167(5):2956–2963PubMed

127.

Selmi C, Ichiki Y, Invernizzi P, Podda M, Gershwin ME (2005) The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol 28(2):73–81PubMedCrossRef

128.

Triger DR (1980) Primary biliary cirrhosis: an epidemiological study. Br Med J 281(6243):772–775PubMedCrossRef

129.

Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP (2011) PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers 29:337–344

130.

Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, Bach N (2006) Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 43(3):525–531PubMedCrossRef

131.

Stellon AJ, Williams R (1986) Increased incidence of menstrual abnormalities and hysterectomy preceding primary biliary cirrhosis. Br Med J Clin Res Ed 293(6542):297–298PubMedCrossRef

132.

Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E (2006) Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 12(22):3537–3545PubMed

133.

Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Mancino MG, Attili AF, Gaudio E (2002) Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology 36(2):297–304PubMedCrossRef

134.

Fagan E, Williams R, Cox S (1977) Primary biliary cirrhosis in mother and daughter. Br Med J 2(6096):1195PubMedCrossRef

135.

Brind AM, Bray GP, Portmann BC, Williams R (1995) Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 36(4):615–617PubMedCrossRef

136.

Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Ghosh K, Dickson ER, Lindor KD, Petersen GM (2007) Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46(3):785–792PubMedCrossRef

137.

Bach N, Schaffner F (1994) Familial primary biliary cirrhosis. J Hepatol 20(6):698–701PubMedCrossRef

138.

Floreani A, Naccarato R, Chiaramonte M (1997) Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol 26(3):737–738PubMedCrossRef

139.

Tsuji K, Watanabe Y, Van De Water J, Nakanishi T, Kajiyama G, Parikh-Patel A, Coppel R, Gershwin ME (1999) Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 13(1):171–178PubMedCrossRef

140.

Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME (2005) Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 25(3):265–280PubMedCrossRef

141.

Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME (2005) Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun 6(7):543–556PubMedCrossRef

142.

Hemminki K, Li X, Sundquist K, Sundquist J (2009) Shared familial aggregation of susceptibility to autoimmune diseases. Arthritis Rheum 60(9):2845–2847PubMedCrossRef

143.

Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF (1996) Natural history of early primary biliary cirrhosis. Lancet 348(9039):1399–1402PubMedCrossRef

144.

Leung PS, Coppel RL, Ansari A, Munoz S, Gershwin ME (1997) Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 17(1):61–69PubMedCrossRef

145.

Bogdanos DP, Vergani D (2006) Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 26(6):633–635PubMedCrossRef

146.

EASL (2009) Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51(2):237–267CrossRef

147.

Gershwin ME, Goetzl EJ, Steinberg AD (1974) Cyclophosphamide: use in practice. Ann Intern Med 80(4):531–540PubMed

148.

Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5(4):230–233PubMedCrossRef

149.

Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56(6):1736–1744PubMedCrossRef

150.

Tonutti E, Visentini D, Bizzaro N (2007) Interpretative comments on autoantibody tests. Autoimmun Rev 6(6):341–346PubMedCrossRef

151.

Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34(3):380–384PubMedCrossRef

152.

Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31(4):325–330PubMedCrossRef

153.

Berkun Y, Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9(5):A319–A324PubMedCrossRef

154.

Bhat A, Naguwa S, Cheema G, Gershwin ME (2010) The epidemiology of transverse myelitis. Autoimmun Rev 9(5):A395–A399PubMedCrossRef

155.

Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9(5):A299–A304PubMedCrossRef

156.

Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34(3):J287–J299PubMedCrossRef

157.

Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9(5):A277–A287PubMedCrossRef

158.

Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9(5):A355–A365PubMedCrossRef

159.

Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34(3):J207–J219PubMedCrossRef

160.

Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314–J321PubMedCrossRef

161.

Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34(3):J234–J246PubMedCrossRef

162.

Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34(3):J276–J286PubMedCrossRef

163.

Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9(5):A293–A298PubMedCrossRef

164.

Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9(5):A342–A349PubMedCrossRef

165.

Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9(5):A325–A329PubMedCrossRef

166.

Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun 34(3):J307–J313PubMedCrossRef

167.

Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34(3):J178–J206PubMedCrossRef

168.

Invernizzi P (2010) Geoepidemiology of autoimmune liver diseases. J Autoimmun 34(3):J300–J306PubMedCrossRef

169.

Lambert JF, Nydegger UE (2010) Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 9(5):A350–A354PubMedCrossRef

170.

Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9(5):A400–A405PubMedCrossRef

171.

Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity–autoantibodies versus autoimmune disease. Autoimmun Rev 9(5):A259–A266PubMedCrossRef

172.

Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9(5):A372–A378PubMedCrossRef

173.

Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9(5):A251–A258PubMedCrossRef

174.

Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjogren’s syndrome. Autoimmun Rev 9(5):A305–A310PubMedCrossRef

175.

Meyer A, Levy Y (2010) Chapter 33: geoepidemiology of myasthenia gravis. Autoimmun Rev 9(5):A383–A386PubMedCrossRef

176.

Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9(5):A379–A382PubMedCrossRef

177.

Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9(5):A387–A394PubMedCrossRef

178.

Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34(3):J226–J233PubMedCrossRef

179.

Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9(5):A330–A334PubMedCrossRef

180.

Ranque B, Mouthon L (2010) Geoepidemiology of systemic sclerosis. Autoimmun Rev 9(5):A311–A318PubMedCrossRef

181.

Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34(3):J220–J225PubMedCrossRef

182.

Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9(5):A335–A341PubMedCrossRef

183.

Segelmark M, Hellmark T (2010) Autoimmune kidney diseases. Autoimmun Rev 9(5):A366–A371PubMedCrossRef

184.

Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9(5):A247–A250PubMedCrossRef

185.

Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9(5):A267–A270PubMedCrossRef

186.

Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34(3):J168–J177PubMedCrossRef

187.

Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9(5):A271–A276PubMedCrossRef

188.

Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9(5):A288–A292PubMedCrossRef

189.

Tomer Y (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34(3):J322–J326PubMedCrossRef

190.

Zeki AA, Schivo M, Chan AL, Hardin KA, Kenyon NJ, Albertson TE et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34(3):J327–J338PubMedCrossRef

Titel: Autoimmunity and Environment: Am I at risk?
verfasst von: Daniel Smyk
Eirini I. Rigopoulou
Harold Baum
Andrew K. Burroughs
Diego Vergani
Dimitrios P. Bogdanos
Publikationsdatum: 01.04.2012
Verlag: Humana Press Inc
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2012
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-011-8259-x

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Autoimmunity and Environment: Am I at risk?

Abstract

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Eingreifen von Umstehenden rettet vor Erstickungstod

Real-World-Daten sprechen eher für Dupilumab als für Op.

Schwindelursache: Massagepistole lässt Otholiten tanzen

Update HNO

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults

Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis

Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease

The Future of Autoimmunity

Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination

Infectious Serologies and Autoantibodies in Hepatitis C and Autoimmune Disease-Associated Mixed Cryoglobulinemia

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Eingreifen von Umstehenden rettet vor Erstickungstod

Real-World-Daten sprechen eher für Dupilumab als für Op.

Schwindelursache: Massagepistole lässt Otholiten tanzen

Update HNO